Design of Novel Exatecan-Amide Linker-Payloads for the Development of Stable, Low-Aggregating, and Highly Efficacious Antibody-Drug Conjugates
. These linker-payloads are promising new leads for the treatment of cancer and represent a generalizable, modular, and advantageous linker platform.
Authors
- Vlad Bacauanu (ORCID: https://orcid.org/0000-0003-3089-0692)
- Esther Kofman
- Ryan V. Quiroz (ORCID: https://orcid.org/0000-0001-6840-9636)
- Laurence Fayadat‐Dilman (ORCID: https://orcid.org/0000-0001-6285-8924)
- Simon B. Lang (ORCID: https://orcid.org/0000-0001-5380-2996)
- Bernhard H. Geierstanger
- Zhong L. Hua
- Michael Judo
- Alan B. Northrup
- Ian Knemeyer (ORCID: https://orcid.org/0000-0001-6254-882X)
- Christian L. Morales
- Daniela M. Tomazela
- Manoj B. Charati (ORCID: https://orcid.org/0009-0000-0680-8236)
- Nancy Zepeda
- John A. Flygare
- Mengxuan Jia (ORCID: https://orcid.org/0000-0001-9173-1084)
- Rebecca Johnson (ORCID: https://orcid.org/0000-0001-6315-278X)
- Evan R. Barry (ORCID: https://orcid.org/0009-0001-7720-1893)
- Qingyun Yan (ORCID: https://orcid.org/0009-0001-2633-8654)
- Peyman Akbari
- Edward P. Bowman
- Huimin Zhong
- Olivia R Chastain
- W Michael Seganish
- Alycia K Uyeoka
- Fan Zhang
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2026-04-30
- DOI
- https://doi.org/10.1021/acs.jmedchem.5c03706
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 14.99
Funders
- Merck